RxDoctor Payments Data

Laura Dziagwa

Family · Indiana, PANPI 1437602968

Payments from drug & device makers

$3,856in general payments, 2019–2025

Across 257 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$955
  • AbbVie$845
  • Lilly USA, LLC$280
  • Daiichi Sankyo Inc.$193
  • Pfizer$178
  • Astellas Pharma US Inc$173
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,77198%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,856 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,529
Medicare patients
27
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$16,801
OzempicSemaglutide15$15,635
Albuterol Sulfate HfaAlbuterol Sulfate21$779
Atorvastatin Calcium19$308
Gabapentin19$307
Famotidine26$190
Losartan Potassium19$181
Potassium Chloride11$165
Lisinopril17$145
Trazodone Hcl16$115
Pantoprazole Sodium18$113
Doxycycline Hyclate27$101
Amlodipine Besylate15$91
Hydrochlorothiazide16$88
Cephalexin14$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$70$16,80128 claims
Novo NordiskOzempic$955$15,63515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Indiana

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →